Company news

Alumis Inc. news in 2026

Alumis Inc.'s news releases, calls and decks from 2026, newest first.

View company

Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

November 12, 2026

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

October 9, 2026

Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

August 14, 2026

Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

August 13, 2026

Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies

August 10, 2026

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

May 13, 2026

Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

March 27, 2026

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

March 18, 2026

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

March 17, 2026

Alumis to Present at the Leerink Partners Global Healthcare Conference

March 2, 2026

Alumis to Participate in Upcoming February Investor Conferences

February 5, 2026

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 9, 2026

Alumis Announces Pricing of Upsized Public Offering of Common Stock

January 7, 2026

Alumis Announces Proposed Public Offering of Common Stock

January 6, 2026

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

January 6, 2026

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

January 5, 2026

Decks in 2026